When did Ionis Pharmaceuticals report Q2 2025 earnings?

Ionis Pharmaceuticals (IONS) reported Q2 2025 earnings on July 30, 2025 before market open.

What were Ionis Pharmaceuticals's Q2 2025 revenue and EPS?

Ionis Pharmaceuticals reported revenue of $452.0M and diluted EPS of $0.86 for Q2 2025.

Did Ionis Pharmaceuticals beat estimates in Q2 2025?

Revenue beat the consensus estimate of $131.7M by $320.3M. EPS beat the consensus estimate of $0.27 by $0.59.

How did Ionis Pharmaceuticals's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 100.7% from $225.3M a year earlier.

Where can I find Ionis Pharmaceuticals's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0000874015-25-000167) directly on SEC EDGAR. The filing index links above go to sec.gov.

Ionis Pharmaceuticals IONS Q2 2025 earnings

Reported July 30, 2025 · Before market open

Revenue$452.0MBeat by $320.3M Diluted EPS$0.86Beat by $0.59

Revenue estimate$131.7M

EPS estimate$0.27

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$190.4M

EPS estimate-$0.92

Financials

Q2 2025

Income statement

See full

Revenue$452.0M+101%

Gross profit$447.9M+103%

Operating income$139.8M+312%

Net income$123.6M+286%

EPS (diluted)$0.70+256%

Balance sheet

See full

Cash & equivalents$297.3M+1.1%

Total debt$794.5M+277%

Total equity$631.7M+140%

Total assets$3.0B+10.9%

Cash flow

See full

Operating cash flow$151.3M+226%

CapEx$12.3M+97.4%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$6.31B-9.0%

Enterprise value$6.81B-0.7%

P/S6.7×-1.8×

Profitability

See full

Gross margin98.9%+0.3pp

Operating margin-28.2%-7.6pp

Net margin-28.4%-7.6pp

Returns & leverage

See full

Return on equity-59.9%-18.1pp

Debt / equity1.3×+0.5×

Current ratio2.9×-4.7×

Segments

By product

See full

Research And Development Revenue$349.3M+128%

Collaborative Agreement Revenue$336.9M+138%

Commercial$102.8M+42.6%

Royalty$70.0M—

Spinraza Royalties$54.3M-4.2%

By segment

See full

Ionis Operations$452.0M+101%

Versus estimates

Revenue

Q1 2026$246.0MBeat by $50.4M Q4 2025$203.0MBeat by $46.9M Q4 2025$156.7MBeat by $3.1M

Q2 2025$452.0MBeat by $320.3M

Q1 2025$131.6MMiss by $19.0M Q4 2024$226.6MBeat by $95.4M

Diluted EPS

Q1 2026-$0.56Beat by $0.29 Q4 2025-$1.41Miss by $0.17 Q4 2025-$0.61Beat by $0.54

Q2 2025$0.86Beat by $0.59

Q1 2025-$0.75Beat by $0.36 Q4 2024-$0.66Beat by $0.43

Ask the moment Ionis Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Ionis Pharmaceuticals report Q2 2025 earnings?: Ionis Pharmaceuticals (IONS) reported Q2 2025 earnings on July 30, 2025 before market open.
What were Ionis Pharmaceuticals's Q2 2025 revenue and EPS?: Ionis Pharmaceuticals reported revenue of $452.0M and diluted EPS of $0.86 for Q2 2025.
Did Ionis Pharmaceuticals beat estimates in Q2 2025?: Revenue beat the consensus estimate of $131.7M by $320.3M. EPS beat the consensus estimate of $0.27 by $0.59.
How did Ionis Pharmaceuticals's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 100.7% from $225.3M a year earlier.
Where can I find Ionis Pharmaceuticals's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0000874015-25-000167) directly on SEC EDGAR. The filing index links above go to sec.gov.